Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies

Author(s): Teruhide Yamaguchi*, Eriko Uchida.

Journal Name: Current Cancer Drug Targets

Volume 18 , Issue 2 , 2018

  Journal Home
Translate in Chinese

Graphical Abstract:


Abstract:

Oncolytic viruses, which include both naturally occurring wild-type viruses/attenuated viruses and genetically modified viruses, have recently been developed for use in innovative cancer therapies. Genetically modified oncolytic viruses possess the unique ability to replicate conditionally as a unique gene therapy product. Since oncolytic viruses exhibit prolonged persistence in patients, viral shedding and transmission to third parties should be major concerns for clinical trials along with the clinical safety and efficacy. Accordingly, studies are now underway to establish the safety and efficacy of oncolytic viruses.

Keywords: Oncolytic virus, gene therapy, cancer therapy, replicating virus, genetically modified viruses, clinical safety and efficacy.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 2
Year: 2018
Page: [202 - 208]
Pages: 7
DOI: 10.2174/1568009617666170222142650
Price: $58

Article Metrics

PDF: 23
HTML: 1
EPUB: 1